Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy. Patients with previously untreated advanced squamous non-small cell lung ...
Squamous cell carcinoma treatment varies by stage, involving surgery, radiation, and systemic therapies based on cancer progression and patient health. Stage 1 focuses on tumor removal, Stage 2 ...
MedPage Today on MSN
Novel drug cuts risk for death by 44% in squamous lung cancer trial
If approved, immunotherapy gotistobart could offer a chemo-free option in second-line sett ...
SurvivorNet on MSN
Lung cancer expert: Promising Gotistobart results, but ‘too soon’ to call it a survival game changer
New Phase 3 lung cancer data show gotistobart nearly doubling survival vs. chemo in squamous NSCLC,b ut experts want more ...
A newly proposed International Association for the Study of Lung Cancer (IASLC) tumor budding–based grading system successfully identified patients with resected lung squamous cell carcinoma (SqCC) at ...
Patients with metastatic squamous non-small cell lung cancer (NSCLC) whose disease progressed following PD-(L)1 inhibitor therapy experienced a median overall survival of 18.5 months with the ...
Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trial. This is an ASCO Meeting ...
Gotistobart continues to show potential as chemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results